VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling

Molecular and Cellular Biology

Volumn 21, Issue 3, 2001, Pages 865-874

  Davidowitz, E J ^a   Schoenfeld, A R ^a   Burk, R D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL DENSITY; CELL DIFFERENTIATION; CELL INTERACTION; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; KIDNEY CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VON HIPPEL LINDAU DISEASE;

ANIMALS; CARCINOMA, RENAL CELL; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL DIVISION; EXTRACELLULAR MATRIX; HIPPEL-LINDAU DISEASE; HUMANS; INTEGRINS; KIDNEY NEOPLASMS; MICE; MICROSCOPY, ELECTRON, SCANNING; MUTATION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0035136533     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.3.865-874.2001     Document Type: Article

References (42)

1. Loss of function of the tissue specific transcription factor HNF1 alpha in renal cell carcinoma and clinical prognosis
2. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box
3. Abnormal nephron development associated with a frame-shift mutation in the transcription factor hepatocyte nuclear factor-1 beta
4. Molecular genetics of polycystic kidney disease
5. Polycystic kidney disease: Primary extracellular matrix abnormality or defective cellular differentiation?
6. Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma
7. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
8. Composition of extracellular matrix and distribution of cell adhesion molecules in renal cell tumors
9. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations
10. Autosomal dominant polycystic kidney disease: Clues to pathogenesis
11. Tumor suppression by the human von Hippel-Lindau gene product
12. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation
13. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex
14. The synchronization of mammalian cells
15. The VHL tumour-suppressor gene paradigm
16. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2
17. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase
18. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex
19. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C
20. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells
21. Identification of the von Hippel-Lindau disease tumor suppressor gene
22. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density
23. Loss of HNF1alpha function in human renal cell carcinoma: Frequent mutations in the VHL gene but not the HNF1alpha gene
24. Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids
25. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
26. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2
27. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene
28. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein
29. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
30. Tissue-specific interactions between nuclear proteins and the aminopeptidase N promoter
31. HNF1 alpha activates the aminopeptidase N promoter in intestinal (Caco-2) cells
32. Renal lesions in von Hippel-Lindau disease: Immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins
33. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
34. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
35. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome
36. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
37. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
38. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von hippel-lindau tumor suppressor protein
39. Murine polycystic kidney epithelial cell lines have increased integrin-mediated adhesion to collagen
40. Molecular basis of autosomal dominant polycystic kidney disease
41. Cystic diseases of the kidney: Role of adhesion molecules in normal and abnormal tubulogenesis
42. The proximal tubule phenotype and its disruption in acute renal failure and polycystic kidney disease